Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the safety and tolerability of AIN457 administered i.v. initially up to 6 months (Part1) with a possible extension of a further 6 months (Part 2 ) in patients with psoriatic arthritis who participated in the core CAIN457A2206 phase II proof-of-concept study
Critère d'inclusion
- Psoriatic arthritis (PsA), which belongs to seronegative spondyloarthropathies (SpA)